콘텐츠로 건너뛰기
Merck

Piroxicam induced pulmonary infiltrates and eosinophilia.

The Journal of rheumatology (1994-08-01)
P Pfitzenmeyer, M Meier, P Zuck, G Peiffer, P Masson, A Turcu, F Piard, P Camus
초록

We describe 2 patients who developed pulmonary infiltrates while being treated with piroxicam. There was no satisfactory explanation other than drug induced lung disease for their illness. They had no exposure to pneumotoxic drugs or aerocontaminants. Microorganisms were not cultured in sputum or bronchoaveolar lavage. There was no underlying illness with possible lung involvement. Pulmonary infiltrates developed during piroxicam therapy, disappeared after drug withdrawal and recurred following rechallenge.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Piroxicam, meets USP testing specifications
Sigma-Aldrich
Piroxicam, ≥98% (TLC)
Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard
Piroxicam, European Pharmacopoeia (EP) Reference Standard
USP
Piroxicam, United States Pharmacopeia (USP) Reference Standard